keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's review

keyword
https://www.readbyqxmd.com/read/29036854/functional-repertoire-of-interleukin-6-in-the-central-nervous-system-a-review
#1
Klaus Heese
In an aging society with dementia imposing an increasing threat to higher brain cognitive functions, understanding the molecular and cellular events of adult neurogenesis is imperative. Interleukin-6 (IL-6), along with its agonistic acting soluble receptor sIL-6R (the combined proteins are also known as Hyper-IL-6), is a promising cytokine that can support neurogenesis under conditions of neurodegeneration when neuron replacement is needed. In contrast to the previously reported gliogenic effects of activation of the IL-6-signal transducer and activator of transcription 3 (STAT3) axis, this review summarizes recent studies showing that IL-6 activation can be neurogenic and has potential therapeutic applications for the treatment of neurodegenerative diseases such as Parkinson's disease...
October 9, 2017: Restorative Neurology and Neuroscience
https://www.readbyqxmd.com/read/29036826/what-can-quantitative-gait-analysis-tell-us-about-dementia-and-its-subtypes-a-structured-review
#2
Ríona Mc Ardle, Rosie Morris, Joanna Wilson, Brook Galna, Alan J Thomas, Lynn Rochester
Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. There is increasing interest in discrete gait characteristics as markers to aid diagnostic algorithms in dementia. This structured review explores the differences in quantitative gait characteristics between dementia and healthy controls, and between four dementia subtypes under single-task conditions: Alzheimer's disease (AD), dementia with Lewy bodies and Parkinson's disease dementia, and vascular dementia. Twenty-six papers out of an initial 5,211 were reviewed and interpreted using a validated model of gait...
October 7, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29035118/clinical-gene-therapy-for-neurodegenerative-diseases-past-present-and-future
#3
Françoise Piguet, Sandro Alves, Nathalie Cartier
Clinical gene therapy has made important advances over the last decade. Among neurological diseases, severe genetic neurodegenerative conditions have been the focus of initial clinical applications. Gene therapy has also addressed complex neurodegenerative diseases, particularly Parkinson's disease, with encouraging results in human patients, demonstrating that specific targeting of central nervous system (CNS) cells is a relevant strategy for severe pathologies and that efficient access to the CNS with viral vectors is an achievable goal...
November 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/29034115/impulse-control-disorder-and-response-inhibition-alterations-in-parkinson-s-disease-a-rare-case-of-totally-absent-functionality-of-the-medial-prefrontal-cortex-and-review-of-literature
#4
Sara Palermo, Rosalba Morese, Maurizio Zibetti, Francesca Dematteis, Stefano Sirgiovanni, Mario Stanziano, Maria Consuelo Valentini, Leonardo Lopiano
This report illustrates a Parkinson's disease (PD) patient with impulse-control disorder (ICD) and selective impairment in response-inhibition abilities as revealed by the performance in a functional magnetic resonance imaging (fMRI) anterior cingulate cortex - sensitive go-nogo task. In line with hypothesis on the role of response-inhibition disabilities in the arising of impulsivity in PD, the patient completely failed the go-nogo task. Moreover, fMRI acquisition revealed absent task-sensitive activity in the anterior cingulate cortex, medial prefrontal, and orbitofrontal cortices for the contrast nogo versus go, which signifying that a hypo-function of this network could be associated with ICD...
November 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/29032502/gut-microbiota-changes-in-the-extreme-decades-of-human-life-a-focus-on-centenarians
#5
REVIEW
Aurelia Santoro, Rita Ostan, Marco Candela, Elena Biagi, Patrizia Brigidi, Miriam Capri, Claudio Franceschi
The gut microbiota (GM) is a complex, evolutionarily molded ecological system, which contributes to a variety of physiological functions. The GM is highly dynamic, being sensitive to environmental stimuli, and its composition changes over the host's entire lifespan. However, the basic question of how much these changes may be ascribed to variables such as population, diet, genetics and gender, and/or to the aging process per se is still largely unanswered. We argue that comparison among studies on centenarians-the best model of healthy aging and longevity-recruited from different geographical areas/populations (different genetics and dietary habits) can help to disentangle the contribution of aging and non-aging-related variables to GM remodeling with age...
October 14, 2017: Cellular and Molecular Life Sciences: CMLS
https://www.readbyqxmd.com/read/29032009/potential-for-stem-cell-treatment-in-manganism
#6
Thatiane C de Moura, Szeifoul Afadlal, Alan S Hazell
Development of manganism (also known as manganese neurotoxicity) is a major complication of manganese exposure in which neurological dysfunction is linked to accumulation of the metal in brain. Due to neuronal cell death in basal ganglia structures, particularly the globus pallidus, functional recovery is limited. Bearing a resemblance to Parkinson's disease, effective treatment for manganism is currently limited. However, the rapidly developing field of stem cell research offers new hope for the treatment of illnesses in which neurodegeneration is a major feature...
October 11, 2017: Neurochemistry International
https://www.readbyqxmd.com/read/29031072/recent-advances-in-discovery-and-development-of-natural-products-as%C3%A2-source-for-anti-parkinson-s-disease-lead-compounds
#7
REVIEW
Hongjia Zhang, Lan Bai, Jun He, Lei Zhong, Xingmei Duan, Liang Ouyang, Yuxuan Zhu, Ting Wang, Yiwen Zhang, Jianyou Shi
Parkinson's disease (PD) is a common chronic degenerative disease of the central nervous system. Although the cause remains unknown, several pathological processes and central factors such as oxidative stress, mitochondrial injury, inflammatory reactions, abnormal deposition of α-synuclein, and cell apoptosis have been reported. Currently, anti-PD drugs are classified into two major groups: drugs that affect dopaminergic neurons and anti-cholinergic drugs. Unfortunately, the existing conventional strategies against PD are with numerous side effects, and cannot fundamentally improve the degenerative process of dopaminergic neurons...
September 30, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29030055/the-heart-of-pd-lewy-body-diseases-as-neurocardiologic-disorders
#8
David S Goldstein, Yehonatan Sharabi
This review provides an update about cardiac sympathetic denervation in Lewy body diseases. The family of Lewy body diseases includes Parkinson's disease (PD), pure autonomic failure (PAF), and dementia with Lewy bodies (DLB). All three feature intra-neuronal cytoplasmic deposits of the protein, alpha-synuclein. Multiple system atrophy (MSA), the parkinsonian form of which can be difficult to distinguish from PD with orthostatic hypotension, involves glial cytoplasmic inclusions that contain alpha-synuclein...
October 10, 2017: Brain Research
https://www.readbyqxmd.com/read/29028874/impaired-self-awareness-of-motor-disturbances-in-parkinson-s-disease
#9
Franziska Maier, George P Prigatano
Traditionally, anosognosia for cognitive or motor impairments in patients with Parkinson's disease (PD) was viewed as unlikely unless the patient was demented. More recent research has suggested that a portion of non-demented PD patients (30%-50%) in fact have impaired subjective awareness (ISA) of their motor impairments (ISAm). This empirical finding has implications for the clinical neuropsychological examination of PD patients and raises theoretical questions relevant to the broader study of anosognosia seen in other patient groups...
September 28, 2017: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
https://www.readbyqxmd.com/read/29028865/clinical-ethics-in-the-context-of-deep-brain-stimulation-for-movement-disorders
#10
Cynthia S Kubu, Paul J Ford
Objective: Discuss common clinical ethical challenges encountered in working with patients who are candidates for deep brain stimulation (DBS) for the treatment of motor symptoms of Parkinson's disease (PD). Method: The relevant literature is reviewed and supplemented by descriptive, ethically challenging cases stemming from decades of combined experience working on DBS teams. We outline ethical arguments and provide pragmatic recommendations to assist neuropsychologists working in movement disorder teams...
September 25, 2017: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
https://www.readbyqxmd.com/read/29027544/long-term-effects-of-exercise-and-physical-therapy-in-people-with-parkinson-disease
#11
REVIEW
Margaret K Mak, Irene S Wong-Yu, Xia Shen, Chloe L Chung
Parkinson disease (PD) is a progressive, neurodegenerative movement disorder with symptoms reflecting various impairments and functional limitations, such as postural instability, gait disturbance, immobility and falls. In addition to pharmacological and surgical management of PD, exercise and physical therapy interventions are also being actively researched. This Review provides an overview of the effects of PD on physical activity - including muscle weakness, reduced aerobic capacity, gait impairment, balance disorders and falls...
October 13, 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/29027011/let-s-make-microglia-great-again-in-neurodegenerative-disorders
#12
REVIEW
Marie-Victoire Guillot-Sestier, Terrence Town
All of the common neurodegenerative disorders-Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and prion diseases-are characterized by accumulation of misfolded proteins that trigger activation of microglia; brain-resident mononuclear phagocytes. This chronic form of neuroinflammation is earmarked by increased release of myriad cytokines and chemokines in patient brains and biofluids. Microglial phagocytosis is compromised early in the disease process, obfuscating clearance of abnormal proteins...
October 12, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29023416/neuro-coagulopathy-blood-coagulation-factors-in-central-nervous-system-diseases
#13
REVIEW
Ciro De Luca, Assunta Virtuoso, Nicola Maggio, Michele Papa
Blood coagulation factors and other proteins, with modulatory effects or modulated by the coagulation cascade have been reported to affect the pathophysiology of the central nervous system (CNS). The protease-activated receptors (PARs) pathway can be considered the central hub of this regulatory network, mainly through thrombin or activated protein C (aPC). These proteins, in fact, showed peculiar properties, being able to interfere with synaptic homeostasis other than coagulation itself. These specific functions modulate neuronal networks, acting both on resident (neurons, astrocytes, and microglia) as well as circulating immune system cells and the extracellular matrix...
October 12, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29022502/pathophysiological-role-of-mitochondrial-potassium-channels-and-their-modulation-by-drugs
#14
Valentina Citi, Vincenzo Calderone, Alma Martelli, Maria Cristina Breschi, Lara Testai
Mitochondria play a central role in ATP-generating processes. Indeed, in mammalian tissues, up to 90% of ATP is generated by mitochondria through the process of oxidative phosphorylation; furthermore, mitochondria are involved in multiple signal transduction pathways. A rapidly expanding body of literature has confirmed that mitochondria play a pivotal role in apoptosis, cardio- and neuro-protection, and various neurodegenerative disorders, ranging from Parkinson's to Alzheimer's disease. It is evident that mitochondria are also the targets of multiple drugs; some of these are exactly designed to influence mitochondrial function, while others have primary targets in other cellular locations but may interact with mitochondria because of the presence of numerous targets on this organelle...
October 12, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29021837/the-bssg-rat-model-of-parkinson-s-disease-progressing-towards-a-valid-predictive-model-of-disease
#15
REVIEW
Jackalina M Van Kampen, Harold A Robertson
ABSTRACT: Parkinson's disease (PD) is a neurodegenerative disorder, classically considered a movement disorder. A great deal is known about the anatomical connections and neuropathology and pharmacological changes of PD, as they relate to the loss of dopaminergic function and the appearance of cardinal motor symptoms. Our understanding of the role of dopamine in PD has led to the development of effective pharmacological treatments of the motor symptoms in the form of dopamine replacement therapy using levodopa and dopaminergic agonists...
September 2017: EPMA Journal
https://www.readbyqxmd.com/read/29021741/the-neuroprotective-role-of-protein-quality-control-in-halting-the-development-of-alpha-synuclein-pathology
#16
REVIEW
Destiny-Love Manecka, Benoît Vanderperre, Edward A Fon, Thomas M Durcan
Synucleinopathies are a family of neurodegenerative disorders that comprises Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Each of these disorders is characterized by devastating motor, cognitive, and autonomic consequences. Current treatments for synucleinopathies are not curative and are limited to improvement of quality of life for affected individuals. Although the underlying causes of these diseases are unknown, a shared pathological hallmark is the presence of proteinaceous inclusions containing the α-synuclein (α-syn) protein in brain tissue...
2017: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/29021353/longitudinal-decline-of-driving-safety-in-parkinson-disease
#17
Ergun Y Uc, Matthew Rizzo, Amy M J O'Shea, Steven W Anderson, Jeffrey D Dawson
OBJECTIVE: To longitudinally assess and predict on-road driving safety in Parkinson disease (PD). METHODS: Drivers with PD (n = 67) and healthy controls (n = 110) drove a standardized route in an instrumented vehicle and were invited to return 2 years later. A professional driving expert reviewed drive data and videos to score safety errors. RESULTS: At baseline, drivers with PD performed worse on visual, cognitive, and motor tests, and committed more road safety errors compared to controls (median PD 38...
October 11, 2017: Neurology
https://www.readbyqxmd.com/read/29021298/prying-into-the-prion-hypothesis-for-parkinson-s-disease
#18
Patrik Brundin, Ronald Melki
In Parkinson's disease, intracellular α-synuclein inclusions form in neurons. We suggest that prion-like behavior of α-synuclein is a key component in Parkinson's disease pathogenesis. Although multiple molecular changes are involved in the triggering of the disease process, we propose that neuron-to-neuron transfer is a crucial event that is essential for Lewy pathology to spread from one brain region to another. In this review, we describe key findings in human postmortem brains, cultured cells, and animal models of disease that support the idea that α-synuclein can act as a prion...
October 11, 2017: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/29018983/nutritional-habits-risk-and-progression-of-parkinson-disease
#19
REVIEW
Roberto Erro, Francesco Brigo, Stefano Tamburin, Mauro Zamboni, Angelo Antonini, Michele Tinazzi
Parkinson disease (PD) is a multifactorial disease, where a genetic predisposition combines with putative environmental risk factors. Mounting evidence suggests that the initial PD pathological manifestations may be located in the gut to subsequently affect brain areas. Moreover, several lines of research demonstrated that there are bidirectional connections between the central nervous system and the gut, the "gut-brain axis" that influences both brain and gastrointestinal function. This opens a potential therapeutic window suggesting that specific dietary strategies may interact with the disease process and influence the risk of PD or modify its course...
October 10, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/29018399/therapeutic-interventions-for-vascular-parkinsonism-a-systematic-review-and-meta-analysis
#20
Adán Miguel-Puga, Gabriel Villafuerte, José Salas-Pacheco, Oscar Arias-Carrión
BACKGROUND: Vascular parkinsonism (VP) is defined as the presence of parkinsonian syndrome, evidence of cerebrovascular disease, and an established relationship between the two disorders. However, the diagnosis of VP is problematic, particularly for the clinician confronted with moving from diagnosis to treatment. Given the different criteria used in the diagnosis of VP, the effectiveness of available therapeutic interventions for this disease are currently unknown. METHODS: To assess the clinical response of all published therapeutic interventions for VP that have been reported in the literature, we conducted a systematic review looking for VP subjects treated with any therapeutic intervention...
2017: Frontiers in Neurology
keyword
keyword
54286
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"